Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

1Life Healthcare

Peloton

In case of a flash sale, scoop up shares of companies that are bound to bounce back.

3 Stocks I Can't Wait to Buy If the Market Crashes Again

A Relative Strength Rating upgrade for Jazz Pharmaceuticals shows improving technical performance.
The post Stock Upgrades: Jazz Pharmaceuticals Shows Rising Relative Strength appeared first on Investor's Business Daily.

Stock Upgrades: Jazz Pharmaceuticals Shows Rising Relative Strength

Despite a poor performance of late, this biotech stock could bounce back.

Is Jazz Pharmaceuticals a Top Stock to Buy Now?

DUBLIN, Sept. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Find the Right Fit (FindTheRightFit-sAML.com), a U.S.

Jazz Pharmaceuticals Launches Initiative to Help Educate People Living with Rare Form of Leukemia

DUBLIN, Sept. 15, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its support of the American Heart Association's sleep health educational content aimed at improving the health and well-being of those struggling with healthy sleep or those living with sleep.

Jazz Pharmaceuticals Announces New Sleep Health Collaboration

SAN FRANCISCO--(BUSINESS WIRE)--Cleave Therapeutics Announces Research Collaboration with Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)

Cleave Therapeutics Announces Preclinical Research Collaboration With Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)

DUBLIN, Sept. 9, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX) to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK).

Jazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies

DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences: Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2020 at 2:45 p.m.

Jazz Pharmaceuticals Announces Participation at Three Upcoming Virtual Investor Conferences

AutoNation

General Motors

Toll Brothers

Vista Outdoor

Earnings yield is a useful ratio for investors who have exposure to both stocks and bonds.

High Earnings Yield Makes These Stocks Worth Buying Right Now

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Jazz (JAZZ) Up 11.4% Since Last Earnings Report: Can It Continue?

Innoviva

Theravance Biopharma

10X Genomics

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Why This Top Venture Capitalist Is Raising Money With a Biotech SPAC

Jazz (JAZZ) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Jazz (JAZZ) Stock

Zoetis

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?

DUBLIN, Aug. 27, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 10 abstracts will be presented at Virtual SLEEP 2020, the 34th annual meeting of the Associated Professional Sleep Societies (APSS) from August 28-30.

Jazz Pharmaceuticals to Present New Data on Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Sunosi® (solriamfetol) at Virtual SLEEP 2020

Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020.

Jazz Pharma (JAZZ) Beats on Q2 Earnings & Sales, Raises View

The drugmaker delivered solid growth in Q2 and upped its full-year outlook.

What's Behind Jazz Pharmaceuticals' Q2 Revenue and Earnings Beats

Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q2 2020 Results - Earnings Call Transcript

DUBLIN, Aug. 4, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2020 and updated its 2020 financial guidance.

Jazz Pharmaceuticals Announces Second Quarter 2020 Financial Results

Xywav has been shown to reduce both cataplexy and excessive daytime sleepiness in narcolepsy patients.

Jazz Pharmaceuticals Wins FDA Approval for Its New Narcolepsy Drug

DUBLIN, July 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020 for the treatment of cataplexy or excessive.

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

DUBLIN, July 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 second quarter financial results on Tuesday, August 4, 2020, after the close of the financial markets. Company management will host a live audio webcast immediately.

Jazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020

Since mid-January Jazz Pharmaceuticals stock is down 28%, falling from a price of $153, to $109.6 at time of writing

Jazz Pharmaceuticals: Undervalued Mid-Sized Pharma Has Assets To Make Up For Falling Xyrem Sales

A new small-cell lung cancer drug approval isn't the only thing the company has going for it.

3 Reasons Jazz Pharmaceuticals Is A Hot Buy Right Now

Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) provided encouraging updates on its commercial efforts in a recent conference call on the lung cancer drug Zepzelca, according to BofA Securities.

BofA Raises Jazz Pharma Estimates After Zepzelca Update

FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.

News for Jazz Pharmaceuticals Stock (JAZZ)